Colorectal Cancer Clinical Trial
Official title:
Evidence Based Colorectal Cancer Screening for the Uninsured - Sub-study
This is a sub-study nested within a previously initiated clinical study (# NCT01946282) focusing on individuals not previously randomized at baseline to the original interventions. The purpose of the sub-study is to evaluate, via a randomized controlled trial design, 3 strategies for promoting screening completion among individuals not up to date with colorectal cancer screening, but assigned to receive screening outreach.
In the previously initiated, ongoing clinical study (# NCT01946282) investigators are testing
a systematic colon cancer screening outreach strategy for increasing screening completion
among uninsured patients, not up-to-date with screening. This is a Sub-study to #NCT01946282
(IRB # 082012-086).
Sub-study description:
The goal of the sub-study is to identify strategies that may further increase rates of 1)
initial participation in colorectal cancer screening, and 2) follow up of abnormal colorectal
cancer screening tests with colonoscopy.
At the time of the sub-study, all patients randomly assigned to receive gift card incentives
have been enrolled. At this time only standard, non-incentive invitations continue to be
mailed to eligible patients.
The sub-study involves 2 parts:
Part 1: Participants scheduled to receive mailed fecal immunochemical test (FIT) outreach for
the first time late in the 2nd year of the study will be randomly assigned to receive one of
three invitation letters, which vary slightly from one another.
For the sub-study, the standard invitation letter will be replaced with one of the three
sub-study letters. All new participants will receive one of the 3 letters during 2
predetermined rounds of invitations (involving n=2,124 individuals). There will be 3
conditions for the sub-study letters and individuals will be randomly assigned 1:1:1 to each
condition. The 3 conditions are as follows:
i) Condition 1 - control letter will be similar to the previous study letters with some
slight wording and grammatical improvements, ii) Condition 2 - cost letter will be the
control letter plus the addition of one sentence informing recipients of the average value of
the FIT procedure and; iii) Condition 3 - cost/future letter will include the average value
of FIT and a sentence assuring patients that should a follow-up test be requested, it will be
provided free of charge.
Rationale and plan for sub-study Part 1: Over nearly 2 years of the program the investigators
have tested a systematic outreach strategy for increasing screening completion among
uninsured patients, not up to date with screening. Through these carefully evaluated
interventions, the investigators have shown that an outreach invitation strategy,
particularly when it includes FIT invitations, markedly increases screening completion among
the uninsured. Thirty-six percent of individuals invited to complete FIT return the test. The
investigators believe this rate may be improved by making changes to the invitation letters.
The sub-study hypothesis is that providing information in the letter about the value of the
kit and attenuating concern about future cost will further increase FIT and follow-up
response rates.
Part 2: In part 2 of the sub-study, participants will receive their FIT results in either a
white envelope (normal results, no immediate follow-up necessary) or a red envelope (abnormal
result, need to follow-up with physician). The only change to this portion of the study is
the color of the envelope patients receive.
Rationale and plan for Part 2: With the current program, the rate of follow-up diagnostic
colonoscopy after abnormal FIT is 58%. Since individuals with abnormal FIT have an increased
chance of having colorectal cancer, identifying alternate strategies to improve compliance
with diagnostic colonoscopy is desirable. Accordingly the sub-study will employ a simple
alerting tactic through the color of the envelope (red for abnormal and white for normal).
The investigators hypothesize that more patients will follow-up after receiving a positive
FIT result as a result of the messaging importance of abnormal tests with a red envelope.
Because the sub-study will be employed in 2 predetermined rounds of invitations,
investigators will have the opportunity to conduct a pre-post analysis of the follow-up rates
to test this hypothesis.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
| Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
| Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
| Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
| Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
| Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
| Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |